Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium
Abstract
BACKGROUND: The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) were compared in patients with advanced urothelial carcinoma.METHODS: Patients with metastatic urothelial carcinoma were randomized to receive either CP (paclitaxel at a dose of 225 mg/m2 and carboplatin [targeted area under the concentration‐time curve (AUC) of 6] given every 21 days) or the standard M‐VAC dosage.RESULTS: Eighty‐five patients were randomized to the respective treatment regimens (41 to CP and 44 to M‐VAC). Response rates and overall survival were similar for both treatment arms. Patients treated with CP had an overall response rate of 28.2% (95% binomial confidence interval, 15.0–44.9%) compared with an overall response rate of 35.9% for the M‐VAC arm (95% binomial confidence interval, 21.2–52.8%) (P = 0.63, Fisher exact test). The median progression‐free survival among patients who were treated with M‐VAC was 8.7 months and was 5.2 months for patients receiving CP (P = 0.24, log‐rank test). At a median follow‐up of 32.5 months, the median survival for patients treated with M‐VAC was 15.4 months versus 13.8 months for patients treated with CP (P = 0.65, log‐rank test). Patients treated with M‐VAC were found to have more severe worst‐degree toxicities compared with patients treated with CP (P = 0.0001). There were no significant differences with regard to quality of life as assessed by the Functional Assessment of Cancer Therapy–Bladder (FACT‐BL) instrument (P = 0.33).CONCLUSIONS: Interpretation of the results of this study must be made with caution because the study failed to reach its accrual goal. Patients treated with CP had a median survival of 13.8 months compared with 15.4 months for patients treated with M‐VAC. Patients treated with CP appeared in general to better tolerate their treatment; however, there were no significant differences noted with regard to measured quality of life parameters. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End PointJournal of Clinical Oncology, 2000
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialThe Lancet, 1999
- Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tractUrology, 1999
- Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trialBritish Journal of Cancer, 1998
- Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.Journal of Clinical Oncology, 1998
- Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen.Journal of Clinical Oncology, 1998
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1997
- Exact Significance Testing to Establish Treatment Equivalence with Ordered Categorical Data1984